Supriya Lifescience Limited
NSE: SUPRIYA BSE: SUPRIYA
Prev Close
745.45
Open Price
754
Volume
485,094
Today Low / High
740.1 / 789.95
52 WK Low / High
330 / 842
Range
707 - 781
Prev Close
745.65
Open Price
750.85
Volume
56,566
Today Low / High
740 / 790
52 WK Low / High
330.5 / 841.7
Range
707 - 782
The stock is currently trading on both the National Stock Exchange (NSE) and Bombay Stock Exchange (BSE). On the NSE, the stock is priced at 743.8 (target range: 707 - 781), reflecting a change of -1.65 (-0.22134%). On the BSE, it is listed at 744.3 (target range: 707 - 782), showing a change of -1.35 (-0.18105%). The stock price is currently in decline on both exchanges, signaling a downtrend. If you're considering investing in this stock, it's important to monitor the situation closely.
Supriya Lifescience Limited Graph
Supriya Lifescience Limited Price Target Predictions: Bullish vs. Bearish Scenarios with Ranges
If you are looking for the target price for Supriya Lifescience Limited T1, T2, T3 for both Bullish and Bearish scenarios, here it is. For Bullish: T1, T2, T3. For Bearish: T1, T2, T3. The stock current price is 743.80, with potential price targets ranging from T1, T2, and T3 in both directions based on market conditions.
| Scenario | Price | Target | Range |
|---|---|---|---|
| Bullish Scenario | 744.30 | 751.74 | 676.57 - 826.92 |
| 759.19 | 607.35 - 911.02 | ||
| 766.63 | 536.64 - 996.62 | ||
| Bearish Scenario | 744.30 | 736.86 | 663.17 - 810.54 |
| 729.41 | 583.53 - 875.30 | ||
| 721.97 | 505.38 - 938.56 |
Overview of Supriya Lifescience Limited
ISIN
INE07RO01027
Industry
Biotechnology
Vol.Avg
350,944
Market Cap
59,863,106,640
Last Dividend
0.8
Official Website
IPO Date
2021-12-28
DCF Diff
368.90
DCF
375
Financial Ratios Every Investor Needs
Stock Dividend of SUPRIYA
| Date | Label | Adj Dividend | Dividend | Record Date | Payment Date | Declaration Date |
|---|---|---|---|---|---|---|
| 2024-09-20 | September 20, 24 | 0.8 | 0.8 | 2024-09-20 | 2024-10-27 | |
| 2023-09-15 | September 15, 23 | 0.6 | 0.6 | 2023-09-15 | 2023-10-29 | |
| 2022-09-01 | September 01, 22 | 0.6 | 0.6 | 2022-09-02 | 2022-10-16 |
Annual Financial Income Report
| Date | Revenue | Co.Rev | GP | GPR | R&D Expenses | G&A Expenses | Operating Income | Net Income | EPS | EBITDA | NIR |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 2024-03-31 | 557.44 Cr | 277.19 Cr | 280.25 Cr | 0.5027 | 1.09 Cr | 23.19 Cr | 157.17 Cr | 119.11 Cr | 14.80 | 183.58 Cr | 0.2137 |
| 2023-03-31 | 460.94 Cr | 180.81 Cr | 280.13 Cr | 0.6077 | 1.24 Cr | 19.23 Cr | 117.17 Cr | 89.86 Cr | 11.16 | 138.39 Cr | 0.1949 |
| 2022-03-31 | 519.37 Cr | 229.89 Cr | 289.49 Cr | 0.5574 | 1.66 Cr | 13.73 Cr | 204.34 Cr | 151.81 Cr | 18.86 | 221.56 Cr | 0.2923 |
| 2021-03-31 | 385.37 Cr | 151.17 Cr | 234.20 Cr | 0.6077 | 0.66 Cr | 10.52 Cr | 166.39 Cr | 123.59 Cr | 16.89 | 178.15 Cr | 0.3207 |
| 2020-03-31 | 311.65 Cr | 162.75 Cr | 148.90 Cr | 0.4778 | 1.06 Cr | 10.48 Cr | 100.81 Cr | 73.40 Cr | 10.03 | 108.96 Cr | 0.2355 |
Annual Financials Balance Sheet
| Date | C&C Equ. | Tot. Assets | Tot. Liab. | Stock. Equity | Tot. Debt | Net Debt | Inv. | PP&E (Net) | Curr. Def. Rev. | Non-Curr. Def. Rev. | LT Invest. | Curr. Liab. |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2024-03-31 | 68.17 Cr | 921.24 Cr | 105.87 Cr | 815.3660 Cr | 5.49 Cr | -62.68 Cr | 85.25 Cr | 457.30 Cr | 14.87 Cr | 0.00 Cr | 63.80 Cr | 76.8940 Cr |
| 2023-03-31 | 85.25 Cr | 820.28 Cr | 120.82 Cr | 699.4590 Cr | 22.47 Cr | -62.78 Cr | 115.77 Cr | 328.06 Cr | 1.66 Cr | 0.00 Cr | 25.30 Cr | 95.7800 Cr |
| 2022-03-31 | 165.78 Cr | 734.76 Cr | 119.08 Cr | 615.6880 Cr | 27.42 Cr | -138.36 Cr | 92.31 Cr | 231.67 Cr | 25.45 Cr | 2.93 Cr | 0.05 Cr | 99.6990 Cr |
| 2021-03-31 | 31.07 Cr | 445.82 Cr | 176.88 Cr | 268.9420 Cr | 72.19 Cr | 41.12 Cr | 72.48 Cr | 175.92 Cr | 17.60 Cr | 20.79 Cr | 0.05 Cr | 146.0190 Cr |
| 2020-03-31 | 1.54 Cr | 336.43 Cr | 187.24 Cr | 149.1930 Cr | 84.52 Cr | 82.98 Cr | 49.46 Cr | 135.01 Cr | 22.91 Cr | 3.68 Cr | 0.05 Cr | 155.3880 Cr |
Annual Financials Cash Flow Statement
| Date | Operating Cash | Investing Cash | Financing Cash | Free Cash | Cash Change | Cash at End | CapEx | Income | Debt Repay | Dividends | Inventory |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 2024-03-31 | 113.3070 Cr | -173.5750 Cr | -22.3590 Cr | -32.3480 Cr | -82.6260 Cr | 74.9560 Cr | -145.6550 Cr | 119.1140 Cr | -16.6250 Cr | -4.8290 Cr | 30.5210 Cr |
| 2023-03-31 | 66.1870 Cr | -133.1450 Cr | -3.3680 Cr | -42.2130 Cr | -70.3260 Cr | 157.5820 Cr | -108.4000 Cr | 123.4870 Cr | -4.6700 Cr | -4.8290 Cr | -23.4580 Cr |
| 2022-03-31 | 48.8010 Cr | -59.8220 Cr | 149.6520 Cr | -11.1030 Cr | 138.6310 Cr | 227.9080 Cr | -59.9040 Cr | 207.2450 Cr | -0.7630 Cr | -4.3910 Cr | -19.8320 Cr |
| 2021-03-31 | 79.9300 Cr | -47.4100 Cr | -14.9310 Cr | 31.6890 Cr | 17.5880 Cr | 92.2930 Cr | -48.2410 Cr | 167.3930 Cr | -11.6660 Cr | -3.9560 Cr | -23.0220 Cr |
| 2020-03-31 | 116.0620 Cr | -24.5250 Cr | -29.2300 Cr | 91.5370 Cr | 62.3070 Cr | 74.7050 Cr | -24.5250 Cr | 96.2270 Cr | -7.6280 Cr | -17.6460 Cr | -18.7260 Cr |
Quarterly Financial Income Report
| Date | Revenue | Co.Rev | GP | GPR | Operating Income | Net Income | EPS | EBITDA | NIR |
|---|---|---|---|---|---|---|---|---|---|
| 2024-12-31 | 185.65 Cr | 61.78 Cr | 123.87 Cr | 0.6672 | 60.99 Cr | 46.78 Cr | 5.82 | 68.05 Cr | 0.2520 |
| 2024-09-30 | 166.10 Cr | 70.40 Cr | 95.70 Cr | 0.5761 | 59.97 Cr | 46.15 Cr | 5.71 | 67.24 Cr | 0.2778 |
| 2024-06-30 | 160.63 Cr | 73.34 Cr | 87.29 Cr | 0.5434 | 57.89 Cr | 44.64 Cr | 5.55 | 64.77 Cr | 0.2779 |
| 2024-03-31 | 158.18 Cr | 79.32 Cr | 78.86 Cr | 0.4986 | 51.59 Cr | 36.93 Cr | 4.59 | 57.69 Cr | 0.2335 |
| 2023-12-31 | 140.07 Cr | 54.62 Cr | 85.45 Cr | 0.6101 | 40.59 Cr | 29.79 Cr | 3.70 | 44.55 Cr | 0.2127 |
Quarterly Financials Balance Sheet
| Date | Cash & Equiv. | Short-Term Inv. | Cash & Short-Term | Net Receivables | Inventory | Total Curr. Assets | PP&E (Net) | Total Assets | Total Liabilities |
|---|---|---|---|---|---|---|---|---|---|
| 2024-09-30 | 77.51 Cr | 9.46 Cr | 86.96 Cr | 105.73 Cr | 107.99 Cr | 413.36 Cr | 522.68 Cr | 1,012.39 Cr | 106.50 Cr |
| 2024-06-30 | 0.00 Cr | 0.00 Cr | 74.96 Cr | 0.00 Cr | 0.00 Cr | 74.96 Cr | 0.00 Cr | 0.00 Cr | -815.37 Cr |
| 2024-03-31 | 74.96 Cr | 11.12 Cr | 74.96 Cr | 111.68 Cr | 85.25 Cr | 397.80 Cr | 457.30 Cr | 921.24 Cr | 105.87 Cr |
| 2023-12-31 | -115.81 Cr | 231.62 Cr | 115.81 Cr | 0.00 Cr | 0.00 Cr | 115.81 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr |
| 2023-09-30 | 104.04 Cr | 16.25 Cr | 120.29 Cr | 84.84 Cr | 98.83 Cr | 410.86 Cr | 373.01 Cr | 843.03 Cr | 89.86 Cr |
Quarterly Financials Cash Flow Statement
| Date | Net Income | Operating Cash Flow | Investing Cash Flow | Financing Cash Flow | Net Cash Change | Cash at End | Cash at Beginning | CapEx | Free Cash Flow |
|---|---|---|---|---|---|---|---|---|---|
| 2024-06-30 | 44.64 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr |
| 2024-03-31 | 36.93 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr |
| 2023-12-31 | 29.79 Cr | 7.92 Cr | 0.00 Cr | 0.00 Cr | 7.92 Cr | 111.96 Cr | 104.04 Cr | 0.00 Cr | 7.92 Cr |
| 2023-09-30 | 23.88 Cr | 7.96 Cr | 0.00 Cr | 0.00 Cr | 7.96 Cr | 104.04 Cr | 96.08 Cr | 0.00 Cr | 7.96 Cr |
| 2023-06-30 | 28.51 Cr | 7.91 Cr | 0.00 Cr | 0.00 Cr | 7.91 Cr | 85.28 Cr | 77.37 Cr | 0.00 Cr | 7.91 Cr |
Splits History
| Date | Label | Split Ratio |
|---|---|---|
| No split history data available. | ||
Similar Stocks: Biotechnology
| Company Name | Symbol | Price | Market Cap | Volume |
|---|---|---|---|---|
| Biocon Limited | BIOCON | ₹331.90 | ₹398,479,140,000.00 | ₹1,860,996.00 |
| Piramal Pharma Limited | PPLPHARMA | ₹220.76 | ₹292,672,172,632.00 | ₹3,206,567.00 |
| Syngene International Limited | SYNGENE | ₹724.60 | ₹290,777,127,354.00 | ₹309,960.00 |
| Concord Biotech Limited | CONCORDBIO | ₹1,712.30 | ₹179,134,319,260.00 | ₹167,947.00 |
| Blue Jet Healthcare Limited | BLUEJET | ₹742.40 | ₹128,780,727,808.00 | ₹402,801.00 |
| Jubilant Ingrevia Limited | JUBLINGREA | ₹674.95 | ₹107,506,805,443.00 | ₹165,388.00 |
| Supriya Lifescience Limited | SUPRIYA | ₹743.80 | ₹59,863,106,640.00 | ₹485,094.00 |
| Dishman Carbogen Amcis Limited | DCAL | ₹210.73 | ₹33,038,902,663.00 | ₹169,506.00 |
| Panacea Biotec Limited | PANACEABIO | ₹504.80 | ₹30,919,375,571.00 | ₹556,110.00 |
| Zota Health Care Limited | ZOTA | ₹884.35 | ₹24,657,917,174.00 | ₹61,116.00 |
Key Executives
Gender: Not Specified
Year Born:
Gender: Not Specified
Year Born: 1955
Gender: female
Year Born:
Gender: Not Specified
Year Born:
Gender: female
Year Born: 1991
Gender: male
Year Born:
Gender: Not Specified
Year Born:
Gender: male
Year Born: 1964
Gender: Not Specified
Year Born: 1990
Gender: female
Year Born: 1958
FAQs about Supriya Lifescience Limited
The CEO is Dr. Satish Waman Wagh.
The current price is ₹743.80.
The range is ₹330-842.
The market capitalization is ₹5,986.31 crores.
The dividend yield is 0.11%.
The P/E ratio is 34.26.
The company operates in the Healthcare sector.
Overview of Supriya Lifescience Limited (ISIN: INE07RO01027) is a leading Biotechnology in India. With a market capitalization of ₹5,986.31 crores and an average daily volume of 350,944 shares, it operates in the Biotechnology. The company last declared a dividend of ₹0.8.